Loading...
•
Sep 30
Concentra Group Holdings Q3 2025 Earnings Report
Concentra Group Holdings reported strong financial results for the third quarter ended September 30, 2025, with significant increases in revenue, net income, and Adjusted EBITDA, driven by growth in patient visits and revenue per visit, as well as strategic acquisitions.
Key Takeaways
Concentra Group Holdings delivered an excellent third quarter in 2025, with revenue increasing by 17.0% to $572.8 million and net income rising by 8.9% to $49.8 million. Adjusted EBITDA also saw a substantial increase of 17.1% to $118.9 million. The company reported strong operational metrics, including a 9.2% increase in patient visits per day and a 4.2% increase in revenue per visit, alongside significant expansion in its occupational health centers and onsite health clinics.
Revenue for Q3 2025 increased by 17.0% to $572.8 million, up from $489.6 million in Q3 2024.
Net income grew by 8.9% to $49.8 million, compared to $45.8 million in the prior year's third quarter.
Adjusted EBITDA rose by 17.1% to $118.9 million, demonstrating strong operational performance.
Patient visits increased by 9.2% to 3,557,697, with revenue per visit growing by 4.2% to $147.31.
Concentra Group Holdings
Concentra Group Holdings
Concentra Group Holdings Revenue by Segment
Revenue by Segment
Occupational Health Centers Revenue
CapyFin.comOnsite Health Clinics Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Concentra raised its financial guidance for the full year 2025, expecting revenue between $2.145 billion and $2.160 billion and Adjusted EBITDA between $425 million and $430 million. The company also targets a net leverage ratio of 3.5x or below by year-end 2025.
Positive Outlook
- Raised full year 2025 revenue guidance to a range of $2.145 billion to $2.160 billion.
- Raised full year 2025 Adjusted EBITDA guidance to a range of $425 million to $430 million.
- Targeting a net leverage ratio of 3.5x or below by the end of 2025.
- Board of Directors declared a cash dividend of $0.0625 per share.
- Board of Directors authorized a share repurchase program of up to $100 million.
Challenges Ahead
- Capital expenditures are expected to be in the range of $80 million to $90 million, trending towards the lower end, which could indicate reduced investment.
- The company faces risks from changes to regulations, new interpretations, or violations of regulations.
- Labor shortages, increased employee turnover or costs, and union activity could significantly increase operating costs.
- The ability to realize reimbursement increases at rates sufficient to keep pace with inflation of costs is a concern.
- Significant legal actions could subject the company to substantial uninsured liabilities.